bluebird bio Inc Stock Research

Market Summary

USD6.28+0.05

Market Closed

0.80%

BLUE Stock Price

BLUE RSI Chart

BLUE Valuation

Market Cap

520.5M

Price/Earnings (Trailing)

-1.15

Price/Sales (Trailing)

107.39

EV/EBITDA

-1.07

Price/Free Cashflow

-1.17

BLUE Price/Sales (Trailing)

BLUE Profitability

EBT Margin

-7079.01%

Return on Equity

-285.7%

Return on Assets

-87.26%

Free Cashflow Yield

-85.71%

BLUE Fundamentals

BLUE Revenue

Revenue Y/Y

962.24%

Revenue Q/Q

-21.9%

BLUE Earnings

Earnings (TTM)

-453.9M

Earnings Y/Y

64.71%

Earnings Q/Q

23.59%

Price Action

52 Week Range

2.878.58

(Low)(High)

Last 7 days

1.3%

Last 30 days

-4.7%

Last 90 days

0.6%

Trailing 12 Months

-14.0%

BLUE Financial Health

Current Ratio

1.27

BLUE Investor Care

Shares Dilution (1Y)

20.78%

Diluted EPS (TTM)

-6.1

Peers (Alternatives to bluebird bio)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	135.3B	26.3B	-2.97%	16.81%	19.8	5.14	2.18%	21.86%
GILD	105.0B	27.1B	-0.99%	30.15%	31.49	3.87	-1.26%	-54.91%
MRNA	73.3B	21.4B	7.28%	27.41%	6.23	3.43	80.80%	66.62%
BIIB	41.9B	10.4B	5.85%	32.49%	14.62	4.04	-6.64%	85.32%
NBIX	10.4B	1.4B	-8.79%	49.41%	178.74	7.49	29.86%	-86.92%
MID-CAP
DNLI	3.9B	-	18.31%	0.06%	-12.88	32.03	-41.50%	-1123.42%
BEAM	3.2B	-	23.33%	-24.11%	-10.12	59.51	215916.67%	21.41%
SMALL-CAP
RCUS	1.7B	432.8M	17.41%	-21.00%	20.97	3.87	1042.97%	128.67%
BBIO	1.4B	-	35.16%	1.79%	-2.74	20.84	745.14%	12.80%
REPL	1.3B	3.1M	-3.43%	39.57%	-8.78	417.83	7.05%	-46.74%
NVAX	886.0M	1.8B	24.61%	-84.52%	-0.67	0.48	53.41%	-22.97%
FATE	574.9M	69.0M	-39.96%	-83.45%	-1.96	8.33	26.22%	-49.52%
SGMO	565.8M	112.1M	28.78%	-35.14%	-3.18	5.05	3.26%	1.99%
VXRT	142.4M	-	42.67%	-74.19%	-1.36	418.24	-71.03%	-64.56%
IBIO	6.7M	-	67.66%	-93.12%	-0.11	3.21	0.51%	-141.69%

Financials for bluebird bio

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-100.0%	null	6,089,000	4,713,000	53,917,200	103,121,400
S&GA Expenses	-5.2%	159,408,000	168,235,000	186,525,000	209,969,000	190,810,000
R&D Expenses	-7.0%	274,250,000	294,780,000	315,584,000	319,946,000	109,614,000
Costs and Expenses	-13.5%	453,335,000	523,951,000	569,876,000	594,573,000	596,687,000
EBITDA	14.5%	-424,982,000.00	-496,821,000.00	-463,487,000.00	-542,731,000.00	-
EBITDA Margin	14.5%	-69.80	-81.59	-8.71	-5.41	-
Earnings Before Taxes	15.1%	-431,041,000.00	-507,475,000.00	-563,094,000.00	-562,380,000.00	-572,124,000.00
EBT Margin	15.1%	-70.79	-83.34	-9.00	-5.61	-
Interest Expenses	-	0	-	-	-	-
Net Income	23.6%	-453,862,000.00	-594,158,000.00	-735,722,000.00	-819,378,000.00	-864,200,000.00
Net Income Margin	23.6%	-74.54	-97.58	-13.83	-8.17	-
Free Cahsflow	14.0%	-446,084,000.00	-518,453,000.00	-565,330,000.00	-650,103,000.00	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-9.3%	520	574	491	594	1,340
Current Assets	-4.2%	160	167	255	337	832
Cash Equivalents	-18.4%	66	81	106	161	402
Inventory	-100.0%	-	1	-	-	-
Net PPE	-20.8%	12	15	11	10	46
Goodwill	0%	6	6	6	6	12
Liabilities	-8.2%	361	393	228	220	469
Current Liabilities	-14.9%	127	149	143	153	267
Shareholder's Equity	-11.8%	159	180	263	374	871
Retained Earnings	-2.0%	-4,020.00	-3,942.21	-3,842.08	-3,719.92	-3,560.00
Additional Paid-In Capital	1.3%	4,181	4,126	4,109	4,096	4,441
Accumulated Depreciation	4.8%	24	23	21	20	59
Shares Outstanding	12.7%	83	74	71	71	69

* denotes actual numbers (not divided by Millions)

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	13.8%	-436.42	-506.32	-557.61	-635.64	-651.11
Share Based Compensation	-25.1%	57	76	98	128	135
Cashflow From Investing	-33.4%	208	312	311	563	650
Cashflow From Financing	-32.8%	-119.65	-90.10	-97.74	-93.95	81

Risks for BLUE

What is the probability of a big loss on BLUE?

98.1%

Probability that bluebird bio stock will be more than 20% underwater in next one year

93.1%

Probability that bluebird bio stock will be more than 30% underwater in next one year.

85.4%

Probability that bluebird bio stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BLUE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if bluebird bio was unfortunately bought at previous high price.

Drawdowns

Returns for BLUE

Cumulative Returns on BLUE

-23.6%

7-Year Cumulative Returns

-50.0%

5-Year Cumulative Returns

-57.9%

3-Year Cumulative Returns

What are the long-term rolling returns for BLUE?

FIve years rolling returns for bluebird bio.

Annualized Returns

Which funds bought or sold BLUE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-25	WHITTIER TRUST CO	unchanged	-	491	2,491	-%
2023-01-25	Lindbrook Capital, LLC	added	165.58	3,661	5,661	-%
2023-01-24	BAILLIE GIFFORD & CO	unchanged	-	1,000	6,000	-%
2023-01-23	Allspring Global Investments Holdings, LLC	reduced	-2.14	11,132	163,132	-%
2023-01-19	Quent Capital, LLC	unchanged	-	19,360	228,360	0.04%
2023-01-18	BOYD WATTERSON ASSET MANAGEMENT LLC/OH	new	-	858	858	-%
2023-01-18	Verition Fund Management LLC	new	-	466,000	466,000	-%
2023-01-12	Hennion & Walsh Asset Management, Inc.	added	11.07	126,000	714,000	0.04%
2022-11-21	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-0.36	66,000	193,000	-%
2022-11-21	FourThought Financial, LLC	unchanged	-	-	-	-%

Latest Funds Activity

Are funds buying BLUE calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BLUE

No. of Funds

bluebird bio News

Schedule 13G FIlings of bluebird bio

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 25, 2023	blackrock inc.	8.9%	7,367,181	SC 13G/A
Jan 12, 2023	millennium management llc	1.2%	973,085	SC 13G/A
Sep 09, 2022	wellington management group llp	0.32%	244,061	SC 13G/A
Aug 01, 2022	millennium management llc	5.4%	3,873,900	SC 13G
Jul 11, 2022	vanguard group inc	4.91%	3,506,909	SC 13G/A
Jul 11, 2022	state street corp	2.55%	1,825,101	SC 13G/A
Jun 03, 2022	tang capital partners lp	5.2%	3,721,056	SC 13G
Apr 11, 2022	state street corp	18.41%	13,151,891	SC 13G/A
Feb 09, 2022	vanguard group inc	10.32%	7,233,590	SC 13G/A
Feb 04, 2022	wellington management group llp	8.76%	6,140,000	SC 13G/A

BLUE Fair Value

Recent SEC filings of bluebird bio

View All Filings

Date Filed	Form Type	Document
Jan 25, 2023	SC 13G/A	Major Ownership Report
Jan 19, 2023	424B5	Prospectus Filed
Jan 19, 2023	8-K	Current Report
Jan 18, 2023	424B5	Prospectus Filed
Jan 13, 2023	4	Insider Trading
Jan 13, 2023	4	Insider Trading
Jan 13, 2023	4	Insider Trading
Jan 12, 2023	SC 13G/A	Major Ownership Report
Jan 09, 2023	3	Insider Trading
Jan 09, 2023	8-K	Current Report

Latest Insider Trading transactions for BLUE

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-11	Colvin Richard A	sold	-4,347	7.8043	-557	chief medical officer
2023-01-11	Obenshain Andrew	sold	-24,802.1	7.8043	-3,178	president and ceo
2023-01-11	Leschly Nick	sold	-33,480.4	7.8043	-4,290	-
2022-12-01	Krawtschuk Christopher	acquired	-	-	50,000	chief financial officer
2022-11-04	Colvin Richard A	sold	-1,398.19	6.4137	-218	chief medical officer
2022-11-04	Obenshain Andrew	sold	-8,100.5	6.4137	-1,263	president and ceo
2022-11-01	Colvin Richard A	acquired	-	-	30,000	chief medical officer
2022-09-01	Klima Thomas J	acquired	-	-	11,000	see remarks
2022-08-19	Cole Jason	sold	-78,472.9	5.5286	-14,194	chief strategy & financial off
2022-08-04	Cole Jason	sold	-32,707.1	4.3914	-7,448	chief strategy & financial off

About bluebird bio

Andrew Obenshain

www.bluebirdbio.com

520

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ÃƒÅ¸-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ÃƒÅ¸-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

BLUE Income Statement

2022-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenues	$ 71	$ 1,019	$ 3,534	$ 2,056
Operating expenses:
Research and development	53,149	73,679	194,864	240,561
Selling, general and administrative	33,402	42,229	106,201	156,763
Cost of product revenue	0	19,385	10,056	35,176
Restructuring expenses	(1,699)	20,175	4,940	24,800
Total operating expenses	84,852	155,468	316,061	457,300
Loss from operations	(84,781)	(154,449)	(312,527)	(455,244)
Interest income, net	383	160	663	733
Other (expense) income, net	7,885	1,342	13,061	24,369
Loss before income taxes	(76,513)	(152,947)	(298,803)	(430,142)
Income tax (expense) benefit	(7)	113	(7)	(169)
Net loss from continuing operations	(76,520)	(152,834)	(298,810)	(430,311)
Net loss from discontinued operations	0	(63,982)	0	(234,015)
Net loss	$ (76,520)	$ (216,816)	$ (298,810)	$ (664,326)
Net loss per share from continuing operations - basic (in dollars per share)	$ (0.94)	$ (2.23)	$ (3.91)	$ (6.36)
Net loss per share from continuing operations - diluted (in dollars per share)	(0.94)	(2.23)	(3.91)	(6.36)
Net loss per share from discontinued operations - basic (in dollars per share)	0	(0.93)	0	(3.46)
Net loss per share from discontinued operations - diluted (in dollars per share)	0	(0.93)	0	(3.46)
Net loss per share - basic (in dollars per share)	(0.94)	(3.16)	(3.91)	(9.81)
Net loss per share - diluted (in dollars per share)	$ (0.94)	$ (3.16)	$ (3.91)	$ (9.81)
Weighted-average number of common shares used in computing net loss per share - basic (in shares)	81,543	68,621	76,361	67,701
Weighted-average number of common shares used in computing net loss per share - diluted (in shares)	81,543	68,621	76,361	67,701
Other comprehensive (loss) income:
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$ (214)	$ (129)	$ (1,719)	$ (401)
Comprehensive loss	(76,734)	(216,945)	(300,529)	(664,727)
Product revenue
Revenue:
Revenue	0	768	2,739	1,492
Other revenue
Revenue:
Revenue	$ 71	$ 251	$ 795	$ 564

BLUE Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 66,478	$ 161,160
Marketable securities	73,155	138,343
Prepaid expenses	8,270	25,628
Receivables and other current assets	12,535	11,389
Total current assets	160,438	336,520
Marketable securities	1,407	97,114
Property, plant and equipment, net	11,535	9,706
Goodwill	5,646	5,646
Operating lease right-of-use assets	288,684	91,532
Restricted cash and other non-current assets	52,388	53,277
Total assets	520,098	593,795
Current liabilities:
Accounts payable	18,622	25,883
Accrued expenses and other current liabilities	64,314	103,958
Operating lease liability, current portion	43,791	23,152
Total current liabilities	126,727	152,993
Operating lease liability, net of current portion	234,422	66,432
Other non-current liabilities	92	93
Total liabilities	361,241	219,518
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at September 30, 2022 and December 31, 2021	0	0
Common stock, $0.01 par value, 125,000 shares authorized; 82,880 and 71,115 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	829	711
Additional paid-in capital	4,181,393	4,096,402
Accumulated other comprehensive loss	(4,630)	(2,911)
Accumulated deficit	(4,018,735)	(3,719,925)
Total stockholders’ equity	158,857	374,277
Total liabilities and stockholders’ equity	$ 520,098	$ 593,795